|
시장보고서
상품코드
2109017
바이오전자 의학 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)Bioelectronic Medicine - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요:
- 전 세계 바이오전자 의학 시장은 2025년에 89억 달러 규모를 기록할 것으로 예상되며, 2034년까지 216억 달러에 달할 것으로 전망됩니다.
- 2026년부터 2034년까지의 예측 기간 동안 이 시장은 연평균 성장률(CAGR) 10.3%로 확대될 것으로 전망됩니다. 이러한 배경에는 자가면역 질환에 대한 신경면역조절 요법의 규제 당국 승인, 만성 통증·운동 장애·염증성 질환의 유병률 증가, 폐쇄 루프형 및 AI 적응형 자극 플랫폼으로의 전환, 그리고 이식형 신경 자극 요법의 적응증 및 보험 적용 경로의 확대 등이 있습니다.
- 제품별로는 2025년에 척수 자극 시스템 부문이 34%의 점유율을 차지하며 바이오전자 의학 시장을 주도했습니다.
- 용도별로는 2025년에 만성 통증 관리 부문이 30%의 점유율을 차지하며 바이오전자 의학 시장을 주도했습니다.
- 최종 사용자별로는 2025년에 병원 부문이 55%의 점유율을 차지하며 바이오전자 의학 시장을 견인했습니다.
- 2025년 시점에서 북미는 바이오전자 의학 시장에서 44%라는 최대 점유율을 차지했으나, 2034년까지는 아시아태평양이 가장 빠른 성장세를 기록할 것으로 예측됩니다.
신경 조절(뉴로모듈레이션) 또는 일렉트로세우티컬 요법이라고도 불리는 바이오전자 의학은 말초 신경, 척수 또는 뇌를 표적으로 한 전기 자극을 전달하여 신경 회로를 조절함으로써, 의약품을 사용하지 않고 만성 질환을 치료하는 이식형 및 비침습형 의료기기를 말합니다. 여기에는 메드트로닉(Medtronic), 보스턴 사이언티픽(Boston Scientific), 애보트(Abbott), 네브로(Nevro) 각사가 제공하는 만성 통증용 척수 자극(SCS) 시스템, 메드트로닉(Medtronic), 보스턴 사이언티픽(Boston Scientific), 애보트(Abbott) 각사가 제공하는 파킨슨병 및 본태성 진전용 심부 뇌 자극(DBS) 시스템, 액소닉스(Axonics, 보스턴 사이언티픽 산하) 및 메드트로닉(Medtronic) 각사가 제공하는 방광·장 기능 장애용 천골 및 경골 신경 조절 시스템, 리바노바(Rivanova)사의 약물 저항성 간질 및 우울증용 미주신경 자극(VNS) 시스템, 그리고 세트포인트 메디컬(SetPoint Medical)사 및 갈바니 바이오일렉트로닉스(Galvani Bioelectronics)사의 자가면역 질환 및 염증성 질환용 미주신경 자극 시스템; 뉴로페이스(Neurostim)사의 간질용 반응형 폐쇄 루프 신경 자극; 인스파이어 메디컬 시스템즈(Inspire Medical Systems)사 및 리바노바(Rivanova)사의 폐쇄성 수면 무호흡 증후군용 설하 신경 자극; 그리고 일렉트로코어(ElectroCore)사의 비침습적 경피적 미주신경 자극이 포함됩니다. 이 시장은 확립된 신경 조절(뉴로모듈레이션) 분야와 신흥 신경면역 바이오일렉트로닉스 치료법의 융합을 특징으로 하며, 2025년에 류마티스 관절염용 최초의 이식형 미주신경 자극 장치가 FDA 승인을 받은 것이 이를 상징적으로 보여줍니다.
바이오일렉트로닉 의료 시장의 주요 시장 성장 촉진요인
- 신경면역 조절의 규제적 타당성이 인정되어, 2025년 FDA가 SetPoint System에 대해 시판 전 승인(PMA)을 부여함으로써 자가면역 질환에 대한 이식형 바이오일렉트로닉 기기에 대한 최초의 규제 경로가 확립되었으며, 관련 적응증에 대한 선례가 제시되었습니다.
- 약물 요법만으로는 충분히 조절할 수 없는 만성 통증, 운동 장애, 약물 내성 간질의 유병률 증가.
- 치료를 개인화하고 장기적인 치료 성과를 향상시키는 폐쇄 루프형, 센싱 기능이 탑재된, AI 적응형 신경 자극 플랫폼으로의 전환.
- 통증, 신경 질환, 비뇨기 질환 적응증 분야에서 환자가 이식형 신경 조절 요법을 이용할 수 있는 기회를 확대하기 위한 임상적 근거 및 보험 적용 경로의 확충.
- 폐쇄성 수면 무호흡증 및 방광·장 기능 장애의 발생률 증가로 인해, 지속적 기도 양압 요법이나 약물 요법을 대체할 수 있는 선택지로 설하 신경 및 천골 신경 조절 시스템의 도입이 확대되고 있습니다.
- 장치의 지속적인 소형화, 배터리 수명 연장, 그리고 MRI 호환성 확보로 인해 적응증 대상 환자층이 확대되고 재시술률이 감소하고 있습니다.
- GSK와 Verily의 합작 회사인 Galvani Bioelectronics나, 전문 신경 조절 기업에 대한 기업 벤처 투자에서 볼 수 있듯이, 의료 기술 기업 및 제약 기업의 신경 면역 및 바이오일렉트로닉스 플랫폼에 대한 투자가 증가하고 있습니다.
바이오전자 의학 시장의 성장에 기여하는 요인
시장 성장 촉진요인
신경면역 조절의 규제상 유효성 인정
바이오전자 의학 시장을 재편하는 근본적인 촉진요인은 치료법으로서의 신경면역 조절에 대한 규제 당국의 승인입니다. 2025년 7월, FDA는 SetPoint Medical사의 'SetPoint System'에 대해 시판 전 승인(PMA)을 부여했습니다. 이는 자가면역 질환, 구체적으로는 생물학적 제제나 표적형 합성 질환 수정 항류마티스제(DMARD)에 대한 반응이 불충분하거나 이에 내성이 없는 성인의 중등도에서 중증 류마티스 관절염에 대해 승인된 최초의 이식형 신경 자극 기기입니다. 이번 승인은 무작위 배정·위약 대조 임상시험인 주요 임상시험 ‘RESET-RA’의 결과를 바탕으로 하며, 신경면역 생체전자 기기에 대한 규제적 로드맵과 시판 전 승인의 선례를 확립하는 것입니다. 이번 승인은 콜린성 항염증 경로에 대한 수십 년에 걸친 연구의 성과로, 경부 미주신경을 자극함으로써 생체 고유의 항염증 및 면역 회복 메커니즘이 활성화된다는 사실이 입증되었습니다. SetPoint System의 승인으로 확립된 선례는 Galvani Bioelectronics사의 비장 신경 자극 플랫폼, 크론병 및 기타 염증성 질환을 대상으로 연구가 진행 중인 미주 신경 자극 프로그램 등 관련 프로그램의 규제상 불확실성을 완화하는 것이며, 임상의, 보험사, 투자자들에게 신경면역 바이오일렉트로닉스 치료법이 연구 단계에서 승인된 표준 치료 옵션으로 전환되었음을 보여줍니다. 신경면역 조절의 규제상 유효성이 인정됨에 따라, 예측 기간 동안 바이오전자 의학에 대한 수요가 유지되고 대상 시장이 재편될 것입니다.
만성 통증, 운동 장애, 약물 저항성 간질의 유병률 증가
만성 통증, 파킨슨병 및 본태성 진전 등의 운동 장애, 그리고 약물 저항성 간질의 유병률 증가는 바이오전자 의학 시장의 기반이 되는 확립된 신경 조절 분야에 대한 수요를 뒷받침하고 있습니다. 약물 치료에 저항성을 보이는 만성 통증(수술 후 요통 증후군이나 척추체 기원의 요통 등)은 메드트로닉(Medtronic), 보스턴 사이언티픽(Boston Scientific), 애보트(Abbott), 네브로(Nevro) 등 각사의 척수 자극 시스템 도입을 촉진하고 있으며, 지속적인 통증 완화 및 오피오이드 사용량 감소와 같은 임상적 근거의 축적이 보험사의 지원을 뒷받침하고 있습니다. 인구 고령화에 따라 파킨슨병 및 본태성 진전의 유병률이 증가하고 있으며, 이는 심부 뇌 자극 시스템의 도입을 촉진하고 있습니다. 한편, 간질 환자 약 3명 중 1명은 약물 요법만으로는 발작 조절을 달성할 수 없어, 미주신경 자극 및 반응형 신경 자극에 대한 수요가 유지되고 있습니다. 이러한 질환의 유병률이 증가하고, 환자와 임상의들이 강화된 약물 요법을 대체할 대안을 모색함에 따라, 통증, 운동 장애, 신경 질환 등 각 적응증에 대한 바이오일렉트로닉 신경 조절 기술에 대한 수요는 예측 기간 동안 지속될 것으로 전망됩니다.
시장 성장 억제요인
바이오전자 의학 시장은 성장을 저해하는 몇 가지 상호 연관된 제약 요인에 직면해 있습니다. 가장 큰 요인은 이식형 시스템 및 수술에 드는 높은 초기 비용입니다. 여기에는 펄스 발생기, 리드선, 외과적 이식, 그리고 수술 후 프로그래밍에 대한 투자가 필요하며, 많은 지역에서 보험사는 영구적 이식을 승인하기 전에 사전 승인이나 시험적 자극 요건을 부과하고 있습니다. 외과적 이식 수술의 침습성과 이에 수반되는 감염, 리드 이동, 하드웨어 관련 합병증 등의 위험으로 인해 적응증이 제한되며, 일부 환자와 임상의는 지속적인 약물 요법을 우선시하여 치료를 연기하는 경향이 있습니다. 최신 범주, 특히 신경면역 미주신경 자극 요법에 대한 보험 환급 및 규제 승인 절차는 미국 이외의 지역에서는 아직 초기 단계에 있으며, 보험 적용 결정, 코딩 및 임상의의 숙련도가 높아지기까지는 시간이 걸릴 것입니다. 배터리 수명, 정기적인 교체 및 충전의 필요성, MRI 호환 표시 요건 등 기기와 관련된 고려 사항들은 환자와 의료 시스템에 지속적인 부담을 주고 있습니다. 임상의 교육 및 이식 수술과 장기적인 프로그래밍이 가능한 전문 신경 조절·신경면역학 센터의 구축은 여전히 주요 대학 병원이나 의뢰 의료 기관에 집중되어 있어, 자원이 부족한 지역이나 지방에서는 접근이 제한되고 있습니다. 이러한 요인들이 복합적으로 작용하여 도입 속도가 더뎌지고 있으며, 공급업체들은 성장을 유지하기 위해 장기적인 안전성, 비용 효율성, 그리고 이식 수술 및 프로그래밍 워크플로우의 효율성을 입증해야 합니다.
자주 묻는 질문
목차
제1장 바이오전자 의학 시장 : 서론
제2장 바이오전자 의학 시장 : 주요 요약
제3장 바이오전자 의학 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 Porter의 Five Forces 분석
제7장 바이오전자 의학 시장 : 평가
제8장 바이오전자 의학 시장 : 경쟁 구도
제9장 바이오전자 의학 시장 : 스타트업의 자금조달 및 투자 동향
제10장 바이오전자 의학 시장 : 기업 개요 및 제품 개요
제11장 KOL(Key Opinion Leader)의 견해
제12장 프로젝트 접근
제13장 DelveInsight에 대해
제14장 면책사항 및 문의
LSHBioelectronic Medicine Market Summary
Overview:
- The global bioelectronic medicine market was valued at USD 8.9 billion in 2025 and is projected to reach USD 21.6 billion by 2034.
- The market is expected to expand at a CAGR of 10.3% during the forecast period 2026-2034, supported by regulatory validation of neuroimmune modulation for autoimmune disease, the rising prevalence of chronic pain, movement, and inflammatory disorders, the shift toward closed-loop and AI-adaptive stimulation platforms, and the expanding indications and reimbursement pathways for implantable neurostimulation.
- By product, the spinal cord stimulation systems segment dominated the bioelectronic medicine market with a 34% share in 2025.
- By application, the chronic pain management segment dominated the bioelectronic medicine market with a 30% share in 2025.
- By end-user, the hospitals segment dominated the bioelectronic medicine market with a 55% share in 2025.
- North America accounted for the largest share of the bioelectronic medicine market at 44% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.
Bioelectronic medicine, also referred to as neuromodulation or electroceutical therapy, refers to implantable and non-invasive devices that deliver targeted electrical impulses to peripheral nerves, the spinal cord, or the brain to modulate neural circuits and treat chronic disease without pharmaceuticals. The scope encompasses spinal cord stimulation (SCS) systems for chronic pain from Medtronic, Boston Scientific, Abbott, and Nevro; deep brain stimulation (DBS) systems for Parkinson's disease and essential tremor from Medtronic, Boston Scientific, and Abbott; sacral and tibial neuromodulation systems for bladder and bowel dysfunction from Axonics (Boston Scientific) and Medtronic; vagus nerve stimulation (VNS) systems for drug-resistant epilepsy and depression from LivaNova, and for autoimmune and inflammatory disease from SetPoint Medical and Galvani Bioelectronics; responsive closed-loop neurostimulation for epilepsy from NeuroPace; hypoglossal nerve stimulation for obstructive sleep apnea from Inspire Medical Systems and LivaNova; and non-invasive transcutaneous vagus nerve stimulation from electroCore. The market is defined by the convergence of established neuromodulation categories with the emerging class of neuroimmune bioelectronic therapies, marked by the 2025 FDA approval of the first implanted vagus nerve stimulator for rheumatoid arthritis.
Bioelectronic Medicine Market Key Growth Drivers
- Regulatory validation of neuroimmune modulation, with the 2025 FDA premarket approval of the SetPoint System establishing the first regulatory pathway for an implanted bioelectronic device in autoimmune disease and opening a precedent for adjacent indications.
- Rising prevalence of chronic pain, movement disorders, and drug-resistant epilepsy that are inadequately controlled by pharmacological therapy alone.
- Shift toward closed-loop, sensing-enabled, and AI-adaptive neurostimulation platforms that personalize therapy and improve long-term outcomes.
- Expanding clinical evidence and reimbursement pathways that broaden patient access to implantable neuromodulation across pain, neurological, and urological indications.
- Growing incidence of obstructive sleep apnea and bladder and bowel dysfunction driving adoption of hypoglossal and sacral neuromodulation systems as alternatives to continuous positive airway pressure and pharmacological management.
- Sustained device miniaturization, extended battery life, and MRI-conditional labeling that broaden patient eligibility and reduce reintervention rates.
- Increasing investment from medical technology companies and pharmaceutical companies in neuroimmune and bioelectronic platforms, exemplified by the GSK-Verily joint venture Galvani Bioelectronics and corporate venture investment in specialist neuromodulation companies.
Key Companies in Bioelectronic Medicine Market
The leading participants in the bioelectronic medicine market include the following:
- Medtronic plc
- Boston Scientific Corporation
- Abbott Laboratories
- LivaNova PLC
- Nevro Corp.
- NeuroPace, Inc.
- Inspire Medical Systems, Inc.
- SetPoint Medical Corporation
- electroCore, Inc.
- Saluda Medical Pty Ltd
Factors Contributing to the Growth of the Bioelectronic Medicine Market
Market Drivers
Regulatory Validation of Neuroimmune Modulation
The foundational driver reshaping the bioelectronic medicine market is the regulatory validation of neuroimmune modulation as a treatment modality. In July 2025, the FDA granted premarket approval to the SetPoint System from SetPoint Medical, the first implanted neurostimulation device approved for an autoimmune indication, specifically moderate-to-severe rheumatoid arthritis in adults who have had an inadequate response to, or cannot tolerate, biologic or targeted synthetic disease-modifying antirheumatic drugs. The approval was supported by the pivotal RESET-RA trial, a randomized, sham-controlled study, and establishes a regulatory pathway and a body of premarket approval precedent for neuroimmune bioelectronic devices. This approval follows decades of research into the cholinergic anti-inflammatory pathway, which established that stimulating the cervical vagus nerve activates the body's innate anti-inflammatory and immune-restorative mechanisms. The precedent set by the SetPoint System approval reduces regulatory uncertainty for adjacent programs, including Galvani Bioelectronics' splenic nerve stimulation platform and vagus nerve stimulation programs under investigation for Crohn's disease and other inflammatory conditions, and it signals to clinicians, payers, and investors that neuroimmune bioelectronic therapy has moved from investigational science to an approved standard of care option. The regulatory validation of neuroimmune modulation sustains demand and reshapes the addressable market for bioelectronic medicine across the forecast period.
Rising Prevalence of Chronic Pain, Movement Disorders, and Drug-Resistant Epilepsy
The rising prevalence of chronic pain, movement disorders such as Parkinson's disease and essential tremor, and drug-resistant epilepsy sustains demand for established neuromodulation categories that anchor the bioelectronic medicine market. Chronic pain that is refractory to pharmacological management, including failed back surgery syndrome and vertebrogenic low back pain, drives adoption of spinal cord stimulation systems from Medtronic, Boston Scientific, Abbott, and Nevro, and the growing clinical evidence base for durable pain relief and opioid-sparing outcomes reinforces payer support. The aging of the population increases the prevalence of Parkinson's disease and essential tremor, driving adoption of deep brain stimulation systems, while roughly one in three patients with epilepsy do not achieve seizure control with medication alone, sustaining demand for vagus nerve stimulation and responsive neurostimulation. As the prevalence of these conditions grows and as patients and clinicians seek alternatives to escalating pharmacological regimens, demand for bioelectronic neuromodulation across pain, movement, and neurological indications is sustained across the forecast period.
Market Restraints
The bioelectronic medicine market faces several interrelated restraints that temper its growth. The foremost is the high upfront cost of implantable systems and procedures, which require investment in the pulse generator, leads, surgical implantation, and follow-up programming, and payers in many geographies apply prior authorization and trial-stimulation requirements before approving permanent implantation. The invasiveness of surgical implantation and the associated risks of infection, lead migration, and hardware-related complications limit candidacy and drive some patients and clinicians to defer therapy in favor of continued pharmacological management. Reimbursement and regulatory pathways for the newest categories, particularly neuroimmune vagus nerve stimulation, remain in the early stages of establishment outside the United States, and coverage determinations, coding, and clinician familiarity will take time to mature. Device-related considerations, including battery longevity, the need for periodic replacement or recharging, and MRI-conditional labeling requirements, add ongoing burden for patients and health systems. Clinician training and the availability of specialized neuromodulation and neuroimmunology centers capable of implantation and long-term programming remain concentrated in leading academic and referral centers, constraining access in lower-resource and rural settings. Together, these factors moderate the pace of adoption and require vendors to demonstrate long-term safety, cost-effectiveness, and streamlined implantation and programming workflows to sustain growth.
Bioelectronic Medicine Market Segment Analysis
The global bioelectronic medicine market is segmented by product (spinal cord stimulation systems, deep brain stimulation systems, sacral and tibial neuromodulation systems, vagus nerve stimulation systems, responsive and closed-loop neurostimulation, hypoglossal nerve stimulation systems, and other peripheral and non-invasive bioelectronic devices), by application (chronic pain management, movement disorders, urinary and bowel dysfunction, obstructive sleep apnea, epilepsy, depression and psychiatric disorders, inflammatory and autoimmune disease, and others), by end-user (hospitals, ambulatory surgical centers, specialty neurology and pain clinics, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).
By Product
Dominant Subsegment: Spinal Cord Stimulation Systems.
The spinal cord stimulation systems category is expected to dominate the market. The spinal cord stimulation segment accounted for a 34% share of the bioelectronic medicine market in 2025. Spinal cord stimulation systems, including the Medtronic Intellis and Inceptiv platforms, the Boston Scientific Precision and WaveWriter platforms, the Abbott Proclaim platform, the Nevro Senza platform, and the Saluda Medical Evoke closed-loop platform, are the leading product category because chronic pain is the largest single indication addressed by implantable neurostimulation and because the category benefits from the deepest and longest-established clinical evidence base and reimbursement coverage among bioelectronic therapies. The dominance of the segment reflects the breadth of competing platforms from the largest medical technology companies, the extension of indications to vertebrogenic low back pain and painful diabetic neuropathy, and the ongoing shift toward rechargeable, MRI-conditional, and closed-loop dosing systems. While deep brain stimulation, sacral and tibial neuromodulation, vagus nerve stimulation, and hypoglossal nerve stimulation are substantial and, in the case of neuroimmune vagus nerve stimulation, faster-growing categories, the scale, competitive depth, and reimbursement maturity of spinal cord stimulation sustain the leadership of the segment across the forecast period.
By Application
Dominant Subsegment: Chronic Pain Management.
The chronic pain management category is expected to dominate the market. The chronic pain management segment accounted for a 30% share of the bioelectronic medicine market in 2025. Chronic pain, including failed back surgery syndrome, complex regional pain syndrome, vertebrogenic low back pain, and painful diabetic neuropathy, is the leading application because it affects a substantial share of adults and because spinal cord stimulation and emerging peripheral nerve stimulation platforms, including the Neuros Medical Altius system, provide durable, opioid-sparing symptom control supported by extensive clinical evidence. The dominance of the segment reflects the size of the eligible patient population, the maturity of reimbursement coverage for spinal cord stimulation across major markets, and the policy emphasis on non-pharmacological pain management amid concern over opioid dependence. While movement disorders, urinary and bowel dysfunction, obstructive sleep apnea, epilepsy, and inflammatory and autoimmune disease are significant and, in several cases, faster-growing applications, the scale and reimbursement depth of chronic pain management sustain the leadership of the segment across the forecast period.
Bioelectronic Medicine Market Region Analysis
Dominant Region: North America
North America accounted for a 44% share of the global bioelectronic medicine market in 2025, representing the highest regional market share globally. The leadership of the region reflects the concentration of the leading device manufacturers, the depth of FDA premarket approval activity, the advanced reimbursement coverage of neuromodulation therapies under Medicare and commercial payers, and the presence of the leading academic epilepsy, movement disorder, and pain centers. The United States is the largest national market, anchored by the 2025 FDA approval of the first neuroimmune vagus nerve stimulation device, the concentration of Medtronic, Boston Scientific, Abbott, Nevro, LivaNova, NeuroPace, Inspire Medical Systems, and SetPoint Medical commercial and research operations, and comprehensive coverage policies for spinal cord stimulation, deep brain stimulation, and sacral neuromodulation. The regulatory leadership, reimbursement maturity, and concentration of vendors and specialist centers reinforce the position of North America as the largest regional market across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region is expanding and modernizing its neurology, pain management, and urology infrastructure, increasing diagnosis rates for chronic pain, epilepsy, and movement disorders, and adopting spinal cord stimulation, deep brain stimulation, and sacral neuromodulation from a growing base. China, Japan, and India are the principal national markets, supported by the construction and modernization of hospitals, the expansion of neurosurgical and pain management specialist training, the aging of the population, and increasing awareness of bioelectronic alternatives to long-term pharmacological management. As hospitals build specialist neuromodulation programs and as awareness of bioelectronic therapy increases, the region increases its adoption of bioelectronic devices from a growing base, positioning Asia-Pacific as the fastest-growing regional market and attracting commercial investment from the leading global vendors.
Regional Commentary
North America
North America leads the market, supported by the concentration of leading vendors, the depth of FDA regulatory activity and premarket approvals, and advanced reimbursement coverage for neuromodulation therapies. The United States dominates the region through its concentration of device manufacturers and specialist implant centers and through the 2025 approval of the first neuroimmune bioelectronic therapy.
Europe
Europe is a substantial market shaped by CE marking and national health technology assessment pathways, established reimbursement for spinal cord stimulation and deep brain stimulation, and the presence of vendors including Medtronic, Boston Scientific, Abbott, LivaNova, and Saluda Medical. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and Galvani Bioelectronics' clinical programs for inflammatory disease are anchored in the region.
Asia-Pacific
Asia-Pacific is the fastest-growing region, driven by hospital modernization, the expansion of specialist neuromodulation and pain management centers, and the growth of the diagnosed patient population for chronic pain, epilepsy, and movement disorders across China, Japan, and India.
Rest of World
The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as specialist neurology, pain management, and urology infrastructure expands, though adoption varies by market and remains concentrated in leading private and academic hospitals.
Bioelectronic Medicine Market Competitive Landscape
The global bioelectronic medicine market is classified as Moderately Consolidated. A group of diversified medical technology companies holds a substantial share of the market through comprehensive neuromodulation portfolios spanning spinal cord stimulation, deep brain stimulation, and sacral neuromodulation, while specialist vendors compete on differentiated single-category platforms in vagus nerve stimulation, responsive neurostimulation, hypoglossal nerve stimulation, and neuroimmune bioelectronic therapy. Competition centers on the breadth of the neuromodulation portfolio, closed-loop and AI-adaptive stimulation capability, MRI-conditional labeling and device longevity, clinical evidence and reimbursement coverage, and the regulatory head start established by the first approved neuroimmune indication. The competitive landscape is evaluated across the following dimensions:
- Market concentration: Moderately consolidated, with Medtronic, Boston Scientific, and Abbott holding a substantial share across spinal cord stimulation, deep brain stimulation, and sacral neuromodulation, alongside specialist vendors including Nevro, LivaNova, NeuroPace, Inspire Medical Systems, SetPoint Medical, electroCore, and Saluda Medical.
- Leading players: Medtronic, Boston Scientific, and Abbott lead across multiple neuromodulation categories; Nevro leads in dedicated spinal cord stimulation, LivaNova leads in vagus nerve stimulation for epilepsy and depression, Inspire Medical Systems leads in hypoglossal nerve stimulation, and SetPoint Medical leads the newly established neuroimmune vagus nerve stimulation category.
- Geographic reach: The leading diversified medical technology companies operate global commercial and regulatory organizations, while specialist vendors including SetPoint Medical, electroCore, and Saluda Medical maintain more concentrated geographic footprints centered on the United States and Europe.
- Product portfolio strength: Competitive advantage rests on the breadth across spinal cord stimulation, deep brain stimulation, sacral and tibial neuromodulation, vagus nerve stimulation, and hypoglossal nerve stimulation, and on closed-loop sensing and adaptive stimulation capability.
- Pipeline strength: Development is concentrated in closed-loop and AI-adaptive stimulation, neuroimmune vagus nerve stimulation for additional autoimmune and inflammatory indications, and miniaturized, longer-lived implantable platforms.
- Strategic partnerships: Collaboration spans the GSK-Verily Galvani Bioelectronics joint venture, the 2025 Galvani-Johnson & Johnson collaboration on graphene-based vagus nerve therapies, and clinical research partnerships with academic centers including the Feinstein Institutes for Medical Research.
- M&A activity: Consolidation has shaped the field, exemplified by Boston Scientific's 2024 acquisition of Axonics for sacral neuromodulation and its acquisition of Relievant Medsystems for vertebrogenic pain, alongside continued corporate venture investment in neuroimmune bioelectronic startups.
- Innovation focus: Innovation is concentrated in closed-loop and sensing-enabled stimulation, exemplified by Medtronic's adaptive Percept platform and Saluda Medical's evoked-response spinal cord stimulation, and in the expansion of neuroimmune vagus nerve stimulation to additional inflammatory indications.
- Regulatory standing: FDA premarket approval, CE marking, and alignment with the classification and safety guidance of the International Neuromodulation Society and the North American Neuromodulation Society are decisive competitive credentials, with the 2025 SetPoint System approval representing a landmark regulatory precedent.
Bioelectronic Medicine Market Recent Developmental Activities
- In July 2025, the FDA granted premarket approval to SetPoint Medical's SetPoint System, the first implanted neuroimmune modulation device approved for moderate-to-severe rheumatoid arthritis. Strategic significance: the approval established the first regulatory pathway for a neuroimmune bioelectronic device and set a precedent for adjacent autoimmune and inflammatory indications.
- In 2024, Boston Scientific completed its acquisition of Axonics, Inc. for approximately USD 3.7 billion, expanding its sacral neuromodulation portfolio for urinary and bowel dysfunction. Strategic significance: the acquisition reinforced Boston Scientific's position across multiple bioelectronic categories and consolidated the sacral neuromodulation segment.
Bioelectronic Medicine Market Segmentation
Bioelectronic Medicine Market Assessment by Product
- Spinal Cord Stimulation Systems
- Deep Brain Stimulation Systems
- Sacral and Tibial Neuromodulation Systems
- Vagus Nerve Stimulation Systems (Neurological and Neuroimmune)
- Responsive and Closed-Loop Neurostimulation
- Hypoglossal Nerve Stimulation Systems
- Other Peripheral and Non-Invasive Bioelectronic Devices
Bioelectronic Medicine Market Assessment by Application
- Chronic Pain Management
- Movement Disorders (Parkinson's Disease and Essential Tremor)
- Urinary and Bowel Dysfunction
- Obstructive Sleep Apnea
- Epilepsy
- Depression and Psychiatric Disorders
- Inflammatory and Autoimmune Disease
- Others
Bioelectronic Medicine Market Assessment by End-User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Neurology and Pain Clinics
- Others
Bioelectronic Medicine Market Assessment by Geography
- North America
- United States Bioelectronic Medicine Market Size in USD million (2023-2034)
- Canada Bioelectronic Medicine Market Size in USD million (2023-2034)
- Mexico Bioelectronic Medicine Market Size in USD million (2023-2034)
- Europe
- Germany Bioelectronic Medicine Market Size in USD million (2023-2034)
- United Kingdom Bioelectronic Medicine Market Size in USD million (2023-2034)
- France Bioelectronic Medicine Market Size in USD million (2023-2034)
- Italy Bioelectronic Medicine Market Size in USD million (2023-2034)
- Spain Bioelectronic Medicine Market Size in USD million (2023-2034)
- Rest of Europe Bioelectronic Medicine Market Size in USD million (2023-2034)
- Asia-Pacific
- China Bioelectronic Medicine Market Size in USD million (2023-2034)
- Japan Bioelectronic Medicine Market Size in USD million (2023-2034)
- India Bioelectronic Medicine Market Size in USD million (2023-2034)
- Australia Bioelectronic Medicine Market Size in USD million (2023-2034)
- South Korea Bioelectronic Medicine Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Bioelectronic Medicine Market Size in USD million (2023-2034)
- Rest of the World
- Middle East Bioelectronic Medicine Market Size in USD million (2023-2034)
- Africa Bioelectronic Medicine Market Size in USD million (2023-2034)
- South America Bioelectronic Medicine Market Size in USD million (2023-2034)
Key Takeaways from the Bioelectronic Medicine Market Report Study
- Market size analysis for the current bioelectronic medicine market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product and technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years, including the 2025 FDA approval of the first neuroimmune bioelectronic device.
- Key companies dominating the global bioelectronic medicine market.
- Various opportunities available for competitors in the bioelectronic medicine market space, including closed-loop stimulation and neuroimmune indication expansion.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current bioelectronic medicine market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for bioelectronic medicine market growth in the future?
Target audience who can benefit from this bioelectronic medicine market report study
- Bioelectronic medicine, neuromodulation, and medical device providers
- Research organizations and consulting companies
- Neurology, pain management, urology, and rheumatology-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in bioelectronic medicine devices
- Various end-users who want to know more about the bioelectronic medicine market and the latest technological developments in the bioelectronic medicine market.
Frequently Asked Questions:
Q1. At what rate is the bioelectronic medicine market expected to grow?
The global bioelectronic medicine market is projected to grow at a compound annual growth rate of 10.3% during the forecast period from 2026 to 2034.
Q2. What is the current and projected size of the bioelectronic medicine market?
The global bioelectronic medicine market was valued at USD 8.9 billion in 2025 and is projected to reach USD 21.6 billion by 2034.
Q3. Which region dominates the bioelectronic medicine market?
North America dominated the bioelectronic medicine market with a 44% share in 2025, driven by the concentration of leading vendors, FDA regulatory leadership, and advanced reimbursement coverage. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by hospital modernization and the expansion of specialist neuromodulation infrastructure across China, Japan, and India.
Q4. What are the key factors driving growth in the bioelectronic medicine market?
The principal drivers are the regulatory validation of neuroimmune modulation following the 2025 FDA approval of the first bioelectronic device for rheumatoid arthritis; the rising prevalence of chronic pain, movement disorders, and drug-resistant epilepsy; the shift toward closed-loop and AI-adaptive neurostimulation; expanding clinical evidence and reimbursement pathways; and the growing incidence of obstructive sleep apnea and bladder and bowel dysfunction.
Q5. Who are the major players in the bioelectronic medicine market?
The market is moderately consolidated and led by Medtronic plc, Boston Scientific Corporation, and Abbott Laboratories, alongside LivaNova PLC, Nevro Corp., NeuroPace, Inc., Inspire Medical Systems, Inc., SetPoint Medical Corporation, electroCore, Inc., and Saluda Medical Pty Ltd. Additional participants including Galvani Bioelectronics, Neuros Medical, Cala Health, and ONWARD Medical compete across neuroimmune, peripheral nerve, and spinal cord stimulation.
Table of Contents
1. Bioelectronic Medicine Market Introduction
- 1.1. Scope of the Report
- 1.2. Market Segmentation
- 1.3. Market Overview at a Glance
2. Bioelectronic Medicine Market Executive Summary
- 2.1. Key Highlights and Market Snapshot
3. Bioelectronic Medicine Market Key Factors Analysis
- 3.1. Market Drivers
- 3.1.1. Regulatory Validation of Neuroimmune Modulation
- 3.1.2. Rising Prevalence of Chronic Pain, Movement Disorders, and Drug-Resistant Epilepsy
- 3.1.3. Shift toward Closed-Loop and AI-Adaptive Neurostimulation
- 3.1.4. Expanding Clinical Evidence and Reimbursement Pathways
- 3.2. Market Restraints
- 3.2.1. High Upfront Cost and Invasiveness of Implantable Systems
- 3.2.2. Nascent Reimbursement Pathways for Neuroimmune Indications
- 3.2.3. Concentration of Specialist Implant Centers
- 3.3. Market Opportunities
- 3.3.1. Neuroimmune Indication Expansion
- 3.3.2. Closed-Loop and AI-Adaptive Platforms
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1. The United States
- 5.2. Europe
- 5.3. Japan
- 5.4. China
6. Bioelectronic Medicine Market Porter's Five Forces Analysis
- 6.1. Bargaining Power of Suppliers
- 6.2. Bargaining Power of Consumers
- 6.3. Threat of New Entrants
- 6.4. Threat of Substitutes
- 6.5. Competitive Rivalry
7. Bioelectronic Medicine Market Assessment
- 7.1. By Product
- 7.1.1. Spinal Cord Stimulation Systems
- 7.1.2. Deep Brain Stimulation Systems
- 7.1.3. Sacral and Tibial Neuromodulation Systems
- 7.1.4. Vagus Nerve Stimulation Systems
- 7.1.5. Responsive and Closed-Loop Neurostimulation
- 7.1.6. Hypoglossal Nerve Stimulation Systems
- 7.1.7. Other Peripheral and Non-Invasive Bioelectronic Devices
- 7.2. By Application
- 7.2.1. Chronic Pain Management
- 7.2.2. Movement Disorders
- 7.2.3. Urinary and Bowel Dysfunction
- 7.2.4. Obstructive Sleep Apnea
- 7.2.5. Epilepsy
- 7.2.6. Depression and Psychiatric Disorders
- 7.2.7. Inflammatory and Autoimmune Disease
- 7.2.8. Others
- 7.3. By End-User
- 7.3.1. Hospitals
- 7.3.2. Ambulatory Surgical Centers
- 7.3.3. Specialty Neurology and Pain Clinics
- 7.3.4. Others
- 7.4. By Geography
- 7.4.1. North America
- 7.4.1.1. United States Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.1.2. Canada Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.1.3. Mexico Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.2. Europe
- 7.4.2.1. Germany Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.2.2. United Kingdom Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.2.3. France Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.2.4. Italy Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.2.5. Spain Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.2.6. Rest of Europe Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.3. Asia-Pacific
- 7.4.3.1. China Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.3.2. Japan Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.3.3. India Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.3.4. Australia Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.3.5. South Korea Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.3.6. Rest of Asia-Pacific Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.4. Rest of the World
- 7.4.4.1. Middle East Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.4.2. Africa Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.4.3. South America Bioelectronic Medicine Market Size in USD million (2023-2034)
- 7.4.1. North America
8. Bioelectronic Medicine Market Competitive Landscape
- 8.1. Competitive Analysis
- 8.2. Company Share Analysis (Premium Offering)
9. Bioelectronic Medicine Market Startup Funding and Investment Trends
10. Bioelectronic Medicine Market Company and Product Profiles
- 10.1. Medtronic plc
- 10.1.1. Company Overview
- 10.1.2. Company Snapshot
- 10.1.3. Financial Overview
- 10.1.4. Product Portfolio
- 10.1.5. Strategic Initiatives / Entropy
- 10.2. Boston Scientific Corporation
- 10.2.1. Company Overview
- 10.2.2. Company Snapshot
- 10.2.3. Financial Overview
- 10.2.4. Product Portfolio
- 10.2.5. Strategic Initiatives / Entropy
- 10.3. Abbott Laboratories
- 10.3.1. Company Overview
- 10.3.2. Company Snapshot
- 10.3.3. Financial Overview
- 10.3.4. Product Portfolio
- 10.3.5. Strategic Initiatives / Entropy
- 10.4. LivaNova PLC
- 10.4.1. Company Overview
- 10.4.2. Company Snapshot
- 10.4.3. Financial Overview
- 10.4.4. Product Portfolio
- 10.4.5. Strategic Initiatives / Entropy
- 10.5. Nevro Corp.
- 10.5.1. Company Overview
- 10.5.2. Company Snapshot
- 10.5.3. Financial Overview
- 10.5.4. Product Portfolio
- 10.5.5. Strategic Initiatives / Entropy
- 10.6. NeuroPace, Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Snapshot
- 10.6.3. Financial Overview
- 10.6.4. Product Portfolio
- 10.6.5. Strategic Initiatives / Entropy
- 10.7. Inspire Medical Systems, Inc.
- 10.7.1. Company Overview
- 10.7.2. Company Snapshot
- 10.7.3. Financial Overview
- 10.7.4. Product Portfolio
- 10.7.5. Strategic Initiatives / Entropy
- 10.8. SetPoint Medical Corporation
- 10.8.1. Company Overview
- 10.8.2. Company Snapshot
- 10.8.3. Financial Overview
- 10.8.4. Product Portfolio
- 10.8.5. Strategic Initiatives / Entropy
- 10.9. electroCore, Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Snapshot
- 10.9.3. Financial Overview
- 10.9.4. Product Portfolio
- 10.9.5. Strategic Initiatives / Entropy
- 10.10. Saluda Medical Pty Ltd
- 10.10.1. Company Overview
- 10.10.2. Company Snapshot
- 10.10.3. Financial Overview
- 10.10.4. Product Portfolio
- 10.10.5. Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
